Cymbopogon winterianus essential oil attenuates bleomycin-induced pulmonary fibrosis in a murine model

dc.commentsCEB54423por
dc.contributor.authorTavares, Lívia A.por
dc.contributor.authorRezende, Allan A.por
dc.contributor.authorSantos, Jymmys L.por
dc.contributor.authorEstevam, Charles S.por
dc.contributor.authorSilva, Ana M. O.por
dc.contributor.authorSchneider, Jaderson K.por
dc.contributor.authorCunha, John L. S.por
dc.contributor.authorDroppa-Almeida, Danielapor
dc.contributor.authorCorreia-Neto, Ivan J.por
dc.contributor.authorCardoso, Juliana C.por
dc.contributor.authorSeverino, Patriciapor
dc.contributor.authorSouto, Eliana B.por
dc.contributor.authorde Albuquerque-Júnior, Ricardo L. C.por
dc.date.accessioned2021-05-12T09:28:17Z
dc.date.available2021-05-12T09:28:17Z
dc.date.issued2021-05-09
dc.date.updated2021-05-11T23:12:37Z
dc.description.abstractThe essential oil of Cymbopogon winterianus (EOCW) is a natural product with antioxidant, anti-inflammatory, and antifibrotic properties. We studied the effect of EOCW in the progression of histological changes of pulmonary fibrosis (PF) in a rodent model. The oil was obtained by hydrodistillation and characterized using gas chromatographymass spectrometry. Intratracheal instillation of bleomycin was performed in 30 rats to induce PF, while Sham animals were subjected to instillation of saline solution. The treatment was performed using daily oral administration of distilled water, EOCW at 50, 100, and 200 mg/kg, and deflazacort (DFC). After 28 days, hemogram and bronchoalveolar lavage fluid (BALF), tissue levels of malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT) were assayed. Histological grading of PF, immunohistochemical expression of -smooth muscle actin (-SMA), and transforming growth factor- (TGF-) were also analyzed. The EOCW major compounds were found to be citronellal, geraniol, and citronellol. EOCW significantly reduced inflammation in BALF, reduced MDA levels, and increased SOD activity. EOCW attenuated histological grading of PF and reduced immunohistochemical expression of -SMA and TGF- in a dose-dependent way, likely due to the reduction of oxidative stress, inflammation, and TGF--induced myofibroblast differentiation.por
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersion
dc.description.sponsorshipThis research was financed by the Coordenação Aperfeiçoamento de Pessoal de Nivel Superior (CAPES), Fundação de Amparo à Pesquisa do Estado de Sergipe (FAPITEC), and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). EBS wishes to acknowledge the sponsorship of the project UIDB/04469/2020 (strategic fund) from the Portuguese Science and Technology Foundation, Ministry of Science and Education (FCT/MEC) through national funds, and was co-financed by FEDER, under the Partnership Agreement PT2020.por
dc.distributioninternationalpor
dc.identifier.citationTavares, Lívia A.; Rezende, Allan A.; Santos, Jymmys L.; Estevam, Charles S.; Silva, Ana M. O.; Schneider, Jaderson K.; Cunha, John L. S.; Droppa-Almeida, Daniela; Correia-Neto, Ivan J.; Cardoso, Juliana C.; Severino, Patricia; Souto, Eliana; de Albuquerque-Júnior, Ricardo L. C., Cymbopogon winterianus essential oil attenuates bleomycin-induced pulmonary fibrosis in a murine model. Pharmaceutics, 13(5), 979, 2021por
dc.identifier.doi10.3390/pharmaceutics13050679por
dc.identifier.issn1999-4923por
dc.identifier.urihttps://hdl.handle.net/1822/72609
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)por
dc.relationUIDB/04469/2020por
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/13/5/679por
dc.rightsopenAccesspor
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/por
dc.subjectpulmonary fibrosispor
dc.subjectterpenespor
dc.subjectWistar ratspor
dc.subjectmyofibroblastspor
dc.subjecthistological labellingpor
dc.subjectimmunohistochemistrypor
dc.subject.wosScience & Technologypor
dc.titleCymbopogon winterianus essential oil attenuates bleomycin-induced pulmonary fibrosis in a murine modelpor
dc.typearticle
dspace.entity.typePublicationen
oaire.citationConferencePlaceSwitzerland
oaire.citationIssue5por
oaire.citationStartPage979por
oaire.citationVolume13por
oaire.versionVoRpor
sdum.journalPharmaceuticspor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
document_54423_1.pdf
Tamanho:
2.18 MB
Formato:
Adobe Portable Document Format